Macrocure (MCUR) Climbs to Session High

October 10, 2016 10:02 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Macrocure (NASDAQ: MCUR) gained Monday morning, rising 30%. Earlier Leap Therapeutics announced the presentation of top-line data from its clinical trial of DKN-01 combination therapy in patients with cholangiocarcinoma at ESMO.

Previously Leap has signed a merger agreement with Macrocure.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Related Entities

Definitive Agreement

Add Your Comment